Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
4,52 USD | 0,00% | 0,00% | -30,99% |
28/03 | Zevra Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023 | CI |
28/03 | Transcript : Zevra Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 |
Attività
Numero di dipendenti: 67
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Proprietary Prodrugs
100,0
%
| 10 | 100,0 % | 27 | 100,0 % | +162,58% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States and Europe
100,0
%
| 10 | 100,0 % | 27 | 100,0 % | +162,58% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Christal Mickle
FOU | Founder | 45 | 30/10/06 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 10/10/23 |
R. Clifton
DFI | Director of Finance/CFO | 51 | 01/04/15 |
Daniel Gallo
CTO | Chief Tech/Sci/R&D Officer | - | 31/01/23 |
Adrian Quartel
CTO | Chief Tech/Sci/R&D Officer | 63 | 04/01 |
Sven Guenther
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/01/07 |
Nichol Ochsner
IRC | Investor Relations Contact | - | 09/08/22 |
Abbi Maher
LAW | General Counsel | - | 31/01/23 |
Joshua Schafer
PRN | Corporate Officer/Principal | 53 | 09/01/23 |
Comptroller/Controller/Auditor | 40 | 13/02/17 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Wendy Dixon
BRD | Director/Board Member | 68 | 25/04/23 |
Tamara Favorito
CHM | Chairman | 65 | 18/08/21 |
Director/Board Member | 56 | 25/04/23 | |
Christal Mickle
FOU | Founder | 45 | 30/10/06 |
Sven Guenther
CTO | Chief Tech/Sci/R&D Officer | 52 | 01/01/07 |
Corey Watton
BRD | Director/Board Member | 54 | 25/04/23 |
John Bode
BRD | Director/Board Member | 49 | 25/04/23 |
Thomas Anderson
BRD | Director/Board Member | 68 | 07/08/23 |
Alvin Shih
BRD | Director/Board Member | 47 | 20/01 |
Neil McFarlane
CEO | Chief Executive Officer | 51 | 10/10/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 45 001 878 | 39 916 898 ( 88,70 %) | 1 575 692 ( 3,501 %) | 88,70 % |
Coordinate società
Zevra Therapeutics, Inc.
1180 Celebration Boulevard Suite 103
34747, Celebration
+321 939 3416
http://zevra.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-30,99% | 189 Mln | |
+5,31% | 70,44 Mrd | |
+10,97% | 8,94 Mrd | |
-16,83% | 4,75 Mrd | |
+43,48% | 4,5 Mrd | |
+3,20% | 3,85 Mrd | |
-21,36% | 2,34 Mrd | |
-29,67% | 2,2 Mrd | |
+8,38% | 1,96 Mrd | |
+3,90% | 1,65 Mrd |
- Borsa valori
- Azioni
- Azione ZVRA
- Società Zevra Therapeutics, Inc.